Global CRISPR Technology Market Report and Forecast 2024-2032

Global CRISPR Technology Market Outlook

The CRISPR technology market size attained a value of USD 2.22 billion in 2023. By 2032, The market is likely to grow at a rate of 23.1% during the forecast period of 2024-2032 to attain a value of USD 14.38 billion by 2032. The growth can be attributed to the increase in the mergers and acquisitions of trategic key players.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

CRISPR Technology: Mechanism of Action and Segmentation

CRISPR, abbreviated for Clustered Regularly Interspaced Short Palindromic Repeats, refers to prokaryotic DNA elements convoluted in adaptive immunity, identified by groups of similar repeats interspaced with non-identical parts called spacers. CRISPR technology is a dynamic tool used for genome modification in mammalian cells enabling researchers to innovate gene-altered variants of higher quality and lower cost than alternative methods, like transcription activator-like effector nuclease or zinc finger nuclease genome editing. 

The protein associated with CRISPR is Cas9 and Cas9 endonuclease is indicated to DNA by a gRNA, which is incorporated as a two-part system made up of trans-activating crRNA and CRISPR RNA or as a sgRNA, wherein the linker connects crRNA and tracrRNA.

Cas9 is incorporated into the CRISPR system, which helps in enabling the rapid expression of genes. This CRISPR Cas9 system also helps in eliminating the risk of inclusion mutagenesis. CRISPR technology is used for the treatment of genetic disorders caused due to the mutation of a single gene and helps eradicate infectious diseases, like HIV.

CRISPR Cas Systems Segmented into Two Types

CRISPR-Cas has evolved from an adaptive immune system to present time's most excellent biotechnology. These ongoing inventions and advancements in this field will drive the growth of the market. According to the CRISPR technology market research report, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Type

• Cas9 and gRNA

• Design Tools

• Plasmid and Vectors

• Other Delivery System Products

Market Breakup by Cas Type

• Cas3 in Type I Systems

• Cas9 in Type II Systems

• Cas10 in Type III Systems

Market Breakup by Application

• Genome Engineering

• Disease Models

• Functional Genomics

• Knockdown/Activation

• Others

Market Breakup by End User

• Academic Research Organizations

• Biopharmaceutical Companies

• Agriculture Biotechnology Companies

• Contract Research Organizations (CROs)

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

CRISPR Technology Market Growth Driving Factors

Companies and investors see the CRISPR-Cas9 technology market as an emerging sector with many foreseen applications in the future. Nonetheless, the passion, endeavours, and financial and industrial firms commend the plausible financial and other societal benefits that are significant. 

The first indicators of the market involve firm investments, fees paid for CRISPR license patents, the range of organisations and firms investing in CRISPR research, and primaeval applications. This increase in investments by private and public firms will help provide a better CRISPR technology market outlook.

According to Harvard reports, since 2013, key companies incorporating CRISPR have received over 600 USD million in venture capital and public market investments.

Expanding Niche of CRISPR Technology

The increased adoption and demand for CRISPR technology are also anticipated to drive the CRISPR technology market expansion. The incorporation of gene editing technologies in different areas, including medicine, biotechnology, and the agricultural sector, is responsible for fuelling the market growth.

The augmentation of genome engineering with possible applications proved to reflect a significant impact on the future of healthcare. The high efficacy of the CRISPR-Cas9 system has been indicated in genome editing studies, which concluded in substantial investments in genome engineering. Nonetheless, many pros and cons also exist, which need cogitation before clinical applications. 

Further, many scientists are working on the shortcomings of CRISPR gene editing technology for more effective results. The plausibility of CRISPR gene editing to change the human genome and alter the disease conditions is excellent but exists with moralistic and social affairs. These ethical issues hamper the CRISPR technology market growth.

North America Accounts for the Largest Share

North America is anticipated to dominate all the regions in the global market. This is due to more product launches, increased awareness, greater expenditure in the healthcare sector and better advancements.

The substantial development in the CRISPR technology market is due to the expanding demand in the food industry for enhanced products with elaborated quality and nutrient embellishment and the pharmaceutical industry for an inclined cure for several diseases. 

Furthermore, the significant ongoing investments by healthcare companies and firms to fulfill the industry needs and flourishing eminence for the gene therapy methodologies with lower turnover time are the protrusive aspects propelling the expansion of the market.

Moreover, companies are spending an enormous amount on reformulating and developing CRISPR technology products and gene therapies. The clinical trial outlook of multiple chronic and genetic disorders has increased in the modern era. This will assist in the CRISPR technology market growth and development.

Therapeutic Landscape

CRISPR technology is mainly utilised in three treatment sectors: cancers, blood disorders, and eye diseases. Other CRISPR applications target other genetic disorders, regenerative medicine, and viral infections.

Clinical Indications of CRISPR Technology

Easy accessibility for injections into the eyes makes it a potential target for in-vivo genetic engineering, making delivery easier. Some indications in the pipeline for CRISPR technology are Usher Syndrome, Stargardt’s disease, Lever Congenital Amaurosis, and Retinitis Pigmentosa 4.  Various researchers are still working on delivering the CRISPR machinery in an AAV vector targeted to photoreceptor cells.

CRISPR technology has been used in cancer to ‘kick in or out’ genes allied to cancer development. In these therapies, immune cells are collected from blood and genetically altered to exhibit tumour-fighting aspects. CRISPR has also been used to develop Chimeric Antigen Receptor T-Cells (CAR-T) therapies for several leukaemia and lymphomas. Genetic engineering of patients’ T-cells ex-vivo is a crucial mechanism in CAR-T therapies. 

CRISPR therapies help modify cells and infuse them into the patient for easy delivery. Current CRISPR treatment for blood disorders raises foetal haemoglobin levels, which can replace defective adult haemoglobin. In this therapy, harvested patients’ blood stem cells are genetically engineered by CRISPR to activate the foetal haemoglobin. 

Chemotherapy is used to eliminate defective stem cells, and in return, the patient’s body is restored with genome-modified stem cells. After that, these cells create a new blood stem population in bone marrow, which further makes red blood cells with foetal haemoglobin.

CRISPR utilised indications are continuously expanding due to enhancements in the delivery capacity and better knowledge of the genetic basis of diseases. Thus, CRISPR seems promising in treating chronic genetic and autosomal recessive disorders. These developing treatments will help in the CRISPR technology market growth. 

Vertex and CRISPR Tx are the first to step forward in treating Duchenne Muscular Dystrophy (DMD). Because of the ease of targeting lipid nanoparticle vectors, liver diseases have also become common targets. CRISPR can also be applicable in the treatment of hepatic disorders. 

The advancement of in-vivo delivery will help in utilising CRISPR to treat more complex genetic diseases, which involve hard-to-target monogenic and multigenic disorders. With expanding base development and prime editing, CRISPR will essentially be able to target all types of genetic disorders. This expanding disease genre will help increase CRISPR technology market value.

Clinical Trial Landscape

In the initial period, researchers and scientists mainly worked on reformulating how CRISPR works in different cell types, its efficiency at cutting DNA, and then developing CRISPR for clinical applications. Later, researchers focused on expanding the CRISPR toolbox by discovering and engineering new CRISPR proteins. 

Emerging Technologies in Pipeline

The first clinical trials in the field of CRISPR therapeutics begin. The Innovative Genomics Institute (IGI) closely tracks the advancement of novel CRISPR-based therapies and the expansion of clinical trials. Clinical trials have also started subsequently in new disease sectors.

Although the number of CRISPR clinical trials is expanding yearly, most current practices using CRISPR-based treatments are still in the early phases. Thus, the CRISPR-based therapies will require a few years to get proper FDA approval.

The emergence of CRISPR genome technology has opened novel prospects in precision medicine. Clinical trials are undergoing in seven treatment sectors: protein-folding disorders, blood disorders, inflammatory disease, cancers, diabetes, infectious diseases, and inherited eye diseases.

Rising Mergers and Acquisitions Driving the Market Growth

In collaboration with Vertex Pharmaceuticals, CRISPR Therapeutics did a clinical trial for the ex vivo CRISPR-based therapy to treat a genetic disease. According to company press reports, over a year, around 19 more individuals have been treated with the same technique. The results of these trials suggest that patients treated with thalassemia show normal haemoglobin levels, and genome-edited cells were also detected. Vertex Pharmaceuticals and CRISPR Therapeutics are collaboratively working on different trial phases in the United States, Europe, and Canada in the three major countries. This therapy has been given special status in Europe and the United States for fast-track approval. 

Beam Therapeutics has also got regulatory approval to move ahead with another Sickle Cell trial to increase foetal haemoglobin.

University of Pennsylvania and Parker Institute tested CAR-T and PD-1 immunotherapy, combined therapies in 2020.

The first CRISPR-based therapy trial consolidated PD-1 and CAR-T immune methods based on CRISPR technology for gene mutation. Researchers concluded that the treatment was safe and had admissible unwanted effects.

All the treatments and therapies are relatively new. Successful results require long-term procedures to supervise the treatment efficacy and to observe the adverse effects. These ongoing clinical trials are emerging as a crucial driver for the CRISPR technology market growth and development.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the CRISPR technology market are as follows:

• Horizon Discovery Group plc

• Sangamo Therapeutics

• GenScript Biotech

• Integrated DNA Technologies, Inc.

• Precision Biosciences

• Beam Therapeutics Inc.

• Thermo Fisher Scientific Inc.

• Intellia Therapeutics

• CRISPR Therapeutics AG

• Vertex Pharmaceuticals Incorporated

• New England Biolabs

• Agilent Technologies, Inc.

• Merck KGaA

Key Highlights of the Report

CRISPR Technology Market Report Snapshots

CRISPR Technology Market Size

CRISPR Technology Market Growth

CRISPR Technology Companies